Lead Product(s): NVX-CoV2373,Matrix-M1
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-CoV2373
Highest Development Status: Phase III Product Type: Vaccine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 03, 2021
Upon Mabion’s successful production of the technical batches, the parties may enter into a broader contract for the production of antigen for NVX-CoV2373 for commercial use, should it be approved by regulatory agencies.